Which Is More Effective, Esbriet or Ofev? A Guide to Comparing Antifibrotic Medications for IPF
•
3 min read
In 2014, the FDA approved two new antifibrotic medications, Esbriet (pirfenidone) and Ofev (nintedanib), on the same day for treating idiopathic pulmonary fibrosis (IPF). This milestone provided new hope for patients with this progressive and fatal lung disease. With two options available, the question of which is more effective, Esbriet or Ofev?, became a central topic of discussion among patients and healthcare providers.
